Determination of Tedizolid Susceptibility Interpretive Criteria for Gram-Positive Pathogens According to Clinical and Laboratory Standards Institute Guidelines

Publication date: Available online 7 November 2017
Source:Diagnostic Microbiology and Infectious Disease
Author(s): Mekki Bensaci, Shawn Flanagan, Taylor Sandison
For effective antibacterial therapy, physicians require qualitative test results using susceptibility breakpoints provided by clinical microbiology laboratories. This article summarizes the key components used to establish the Clinical Laboratory Standards Institute (CLSI) breakpoints for tedizolid. First, in vitro studies using recent surveillance and clinical trial isolates ascertained minimal inhibitory concentration (MIC) distributions against pertinent organisms, including staphylococci, streptococci, and enterococci. Studies in animal models of infection determined rates of antibacterial efficacy and survival following administration of tedizolid phosphate at doses equivalent to those in humans. Pharmacokinetic and pharmacodynamic analyses examined the relationship between plasma concentrations and MICs against the target organism. Finally, clinical trials assessed clinical and microbiologic outcomes by MIC. All these data were evaluated and combined to obtain the ratified CLSI susceptibility criteria for tedizolid of ≤0.5μg/mL for Staphylococcus aureus, Streptococcus pyogenes, Streptococcus agalactiae, and Enterococcus faecalis and ≤0.25μg/mL for Streptococcus anginosus group.



from ! ORL Sfakianakis via paythelady.61 on Inoreader http://ift.tt/2m5aC54
via IFTTT